Work

75P Efficacy and updated safety results from pivotal phase II trial 201 of naxitamab (Hu3F8): A humanized GD2-targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)

Year: 2020

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.10.563

Authors: J. Mora, G.C. Chan, D.A. Morgenstern, K. Nysom, M. Bear, L. Worsaae Dalby, S. Lisby, B.H. Kushner

Institutions: Hospital Sant Joan de Déu Barcelona, Queen Mary Hospital, University of Hong Kong, Hospital for Sick Children, Rigshospitalet, Riley Hospital for Children, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Neuroblastoma Research and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Y-mAbs Therapeutics

OpenAlex ID: W3111638372

FWCI: 0.649

Cites:

Cited by: 8

Related to: 10